Background Previous studies have shown inconsistent results on the association between diabetes mellitus (DM) and some clinical outcomes. We conducted a meta-analysis of observational studies to assess effect of DM on clinical outcomes after coronary stenting. Methods We searched for studies without language restriction in PubMed, Embase and Cochrane library prior to 2012. The clinical outcomes including in-stent restenosis (ISR), major adverse cardiac events (MACE), stent thrombosis (ST), target lesion revascularization (TLR) and target vessel revascularization (TVR). Adjusted odds ratio (OR), and the corresponding 95% confidence interval (95% CI) was summarized. Results 55 studies involving 128,084 total patients (38,416 DM patients and 89,668 controls) were eligible for our analysis. Overall, there were significant associations between DM and ISR (OR = 1.70, 95% CI: 1.53–1.89, I2 = 0.0%), MACE (OR = 1.54, 95% CI: 1.36–1.73, I2 = 29.0%), ST (OR = 2.01, 95% CI: 1.36–2.97, I2 = 47.7%), TLR (OR = 1.46, 95% CI: 1.26–1.68, I2 = 43.3%) as well as TVR (OR = 1.33, 95% CI: 1.17–1.51, I2 = 48.3). Subgroup analysis showed that the associations were similar between BMS and DES implantation. Moreover, there was no significant association in the ST subgroup after 1–3 years follow-up. Conclusions Our meta-analysis suggests that after coronary stent implantation, DM is associated with ISR, MACE, ST, TLR and TVR. DM appears to be a vital risk factor of these clinical outcomes.
References
[1]
Jensen LO, Thayssen P, Mintz GS, Egede R, Maeng M, et al. (2008) Comparison of intravascular ultrasound and angiographic assessment of coronary reference segment size in patients with type 2 diabetes mellitus. Am J Cardiol 101: 590–595.
[2]
Nasu K, Tsuchikane E, Katoh O, Fujita H, Surmely JF, et al. (2008) Plaque characterisation by Virtual Histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart 94: 429–433.
[3]
Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, et al. (2003) Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348: 2294–2303.
[4]
Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, et al. (2002) Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol 40: 418–423.
[5]
Mehran R, Dangas GD, Kobayashi Y, Lansky AJ, Mintz GS, et al. (2004) Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 43: 1348–1354.
[6]
Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, et al. (2004) Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110: 3627–3635.
[7]
Hong SJ, Kim MH, Ahn TH, Ahn YK, Bae JH, et al. (2006) Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart 92: 1119–1124.
[8]
Kishi K, Hiasa Y, Tomokane T, Yamaguchi K, Ogura R, et al. (2005) Efficacy of stenting after rotational atherectomy for ostial LAD and ostial LCX stenosis in patients with diabetes. J Invasive Cardiol 17: 14–18.
[9]
Ma S, Yang D, Zhang X, Tang B, Li D, et al. (2011) Comparison of restenosis rate with sirolimus-eluting stent in STEMI patients with and without diabetes at 6-month angiographic follow-up. Acta Cardiol 66: 603–606.
[10]
Radke PW, Friese K, Buhr A, Nagel B, Harland LC, et al. (2006) Comparison of coronary restenosis rates in matched patients with versus without diabetes mellitus. Am J Cardiol 98: 1218–1222.
[11]
Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, et al. (2007) Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 154: 688–693.
[12]
Rathore S, Kinoshita Y, Terashima M, Katoh O, Matsuo H, et al. (2010) A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. EuroIntervention 5: 841–846.
[13]
Mahmud E, Bromberg-Marin G, Palakodeti V, Ang L, Creanga D, et al. (2008) Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol 51: 2385–2395.
[14]
Zhang F, Dong L, Ge J (2010) Meta-analysis of five randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus. Am J Cardiol 105: 64–68.
[15]
Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, et al. (2004) Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 43: 8–14.
[16]
Kornowski R, Fuchs S (2004) Optimization of glycemic control and restenosis prevention in diabetic patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 43: 15–17.
[17]
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
[18]
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012.
[19]
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: 3rd Symposium on Systematic Reviews: Beyond the Basics, Oxford, UK, 3–55 July 2000. Available: http://wwwohrica/programs/clinical_epide？miology/oxfordhtml.
Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326: 219.
[22]
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
[23]
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229–234.
[24]
Laakso M (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48: 937–942.
[25]
Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, et al. (2004) Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 109: 2290–2295.
[26]
Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, et al. (1996) Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 94: 1818–1825.
[27]
Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al. (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315–1323.
[28]
Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al. (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350: 221–231.
[29]
Van Belle E, Chmait A, Bauters C, Lablanche JM (2004) Angioplasty in the diabetic patient. J Invasive Cardiol 16: 23–27.
[30]
Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, et al. (2012) Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 345: e5170.
[31]
Fath-Ordoubadi F, Barac Y, Abergel E, Danzi GB, Kerner A, et al. (2012) Gender impact on prognosis of acute coronary syndrome patients treated with drug-eluting stents. Am J Cardiol 110: 636–642.
[32]
Nakamura M, Yokoi H, Hamazaki Y, Watarai M, Kijima M, et al. (2010) Impact of insulin-treated diabetes and hemodialysis on long-term clinical outcomes following sirolimus-eluting stent deployment. Insights from a sub-study of the Cypher Stent Japan Post-Marketing Surveillance(Cypher J-PMS) Registry. Circ J 74: 2592–2597.
[33]
Zahn R, Hamm CW, Schneider S, Richardt G, Kelm M, et al. (2010) Coronary stenting with the sirolimus-eluting stent in clinical practice: final results from the prospective multicenter German Cypher Stent Registry. J Interv Cardiol 23: 18–25.
[34]
Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al. (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293: 2126–2130.
[35]
Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, et al. (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115: 1051–1058.
[36]
Drozd J, Wojcik J, Malek R, Korona B, Zapolski T, et al. (2010) Acute coronary syndrome - a frequent clinical manifestation of bare metal in-stent restenosis. Kardiol Pol 68: 637–645.
[37]
Hong SN, Ahn Y, Yoon NS, Lee KH, Kim YS, et al. (2007) Usefulness of serum N-terminal pro-brain natriuretic peptide to predict in-stent restenosis in patients with preserved left ventricular function and normal troponin I levels. Am J Cardiol 99: 1051–1054.
[38]
Skowasch D, Jabs A, Andrie R, Luderitz B, Bauriedel G (2005) Progression of native coronary plaques and in-stent restenosis are associated and predicted by increased pre-procedural C reactive protein. Heart 91: 535–536.
[39]
Kufner S, de Waha A, Tomai F, Park SW, Lee SW, et al. (2011) A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. Am Heart J 162: 740–747.
[40]
Sidhu MS, Brown JR, Yang RC, DeVries JT, Jayne JE, et al. (2010) Real world, long-term outcomes comparison between paclitaxel-eluting and sirolimus-eluting stent platforms. J Interv Cardiol 23: 167–175.
